Descriptive only
Serious adverse events
Polycystic ovary syndrome
longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)
3
Randomized trials
3
Treatments
224
Participants
3
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 3 trials. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagOutcome assessment, analysis set: confounded with design: completers 1, safety 2
- FlagRisk of bias, blinding: confounded with design: double_blind 2, open_label 1
- NoteOutcome assessment, time point: selected time points span 12 to 36 weeks
- NoteRisk of bias, funding: mixed: industry 1, mixed 1, non_industry 1
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAXAPCOS | 36 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2018 | premenopausal women 18 to 45 years; PCOS by modified NIH 1990; BMI 30 or more; no diabetes |
| LIPT | 26 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2014 | Rotterdam PCOS; BMI over 25 or insulin resistance; non hormonal contraception; no diabetes or CVD |
| NCT03151005 | 12 | completers | not stated | not stated | not stated | not stated | not stated | not stated | open_label | non_industry | 2017 | Rotterdam PCOS, BMI 24 kg/m2 or more, age 18 to 50 years |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| SAXAPCOS | A1 | LIRA_SC | 36 | arm, events | 0 / 55 | R0022023:Results | |||
| SAXAPCOS | A2 | PLACEBO | 36 | arm, events | 0 / 27 | R0022023:Results | |||
| LIPT | A1 | LIRA_SC | 26 | arm, events | 2 / 48 | registry:adverse_events | |||
| LIPT | A2 | PLACEBO | 26 | arm, events | 1 / 24 | registry:adverse_events | |||
| NCT03151005 | A1 | OTHER_ACTIVE_cyproterone_ethinylestradiol | 12 | arm, events | 0 / 35 | registry:adverse_events | |||
| NCT03151005 | A2 | LIRA_SC | 12 | arm, events | 0 / 35 | registry:adverse_events |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.